EP3140303
Imídasó[4,5-c]kínólín-2-ón-efnasambönd og notkun þeirra við meðhöndlun á krabbameini
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
5.5.2015EP published:
28.3.2018EP application number:
15724351.0
EP translation filed:
16.5.2018Grant published:
15.6.2018EPO information:
European Patent Register
Max expiry date:
4.5.2035Expiry date:
4.5.2024
Title:
IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER
Timeline
Today
5.5.2015EP application
28.3.2018EP Publication
16.5.2018Translation submitted
15.6.2018Registration published
4.5.2024Expires
Owner
Name:
Astrazeneca ABAddress:
151 85 Södertälje, SE
Inventor
Name:
BARLAAM, Bernard ChristopheAddress:
Cambridge, CB4 OWG, GB
Name:
PIKE, Kurt GordonAddress:
Cambridge CB4 OWG, GB
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201461990232 PDate:
8.5.2014Country:
US
Classification
Categories:
C07D 471/04, A61K 31/437, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 4
Paid: 17.5.2018
Expires: 4.5.2019
Payer: Árnason Faktor
Number: 5
Paid: 5.4.2019
Expires: 4.5.2020
Payer: Árnason Faktor
Number: 6
Paid: 7.4.2020
Expires: 4.5.2021
Payer: Árnason Faktor ehf.
Number: 7
Paid: 8.4.2021
Expires: 4.5.2022
Payer: Árnason Faktor ehf.
Number: 8
Paid: 5.4.2022
Expires: 4.5.2023
Payer: Árnason Faktor ehf.
Number: 9
Paid: 12.4.2023
Expires: 4.5.2024
Payer: Árnason Faktor ehf.